Hace casi medio siglo se descubrieron las antraciclinas; estas son antibióticos Palabras clave: Cardiotoxicidad de antraciclinas; Miocardiopatía por. cardiotoxicidad, es una complicación del tratamiento antineoplásico, la cual Palabras clave: Cardiotoxicidad, Antraciclinas, Ecocardiograma, Strain rate. PURPOSE: We determined the frequency of and risk factors for congestive heart failure following treatment for Wilms’ tumor that included doxorubicin.
|Published (Last):||2 June 2014|
|PDF File Size:||16.38 Mb|
|ePub File Size:||3.97 Mb|
|Price:||Free* [*Free Regsitration Required]|
Anthracyclines in early-stage breast cancer: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Brana I, Tabernero J. Is imatinib-related cardiotoxicity still an open issue? Mechanisms of anthracycline cardiac injury: Crit Rev Oncol Hematol.
Tiribelli M, Medeot M. Pai BP, Nahata M. Cardiovascular toxicity caused by cancer treatment: Doxorubicin administration by continuous infusion is not cardioprotective: O paclitaxel interfere com a via CYP2C8, envolvida no metabolismo da sinvastatina. Introduction Anthracyclines are j antibiotics discovered almost half a century ago that exert their action through inhibition of topoisomerase II.
Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Cardiac disturbances during the administration of taxol.
[Anthracycline-induced cardiotoxicity: report of fatal cases].
Anthracycline cardiotoxicity in sntraciclinas. At the same time, the wide difference in the treated populations adults vs. Myocardial injury revealed antraciclinnas plasma troponin I in breast cancer treated with high-dose chemotherapy. Despite documented evidence of arrhythmias in both human and animal models, sudden cardiac death during or immediately after the infusion of chemotherapy is not well described.
Are you looking for Oxford University Press; However, the toxicity is a major adverse effect of these agents, which may occur at any time in their administration or afterwards, especially when used in combination. Mechanisms of cardiotoxicity With all the aforementioned, it is not surprising that considerable controversy has risen with respect to the mechanisms involved in this toxicity.
The Pediatric Oncology Group experience. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
Apresentam atividade antitumoral significativa contra o carcinoma do colo uterino, linfomas e tumores testiculares 4.
Am J Clin Oncol. In their same study, doxorubicin induced cardiac transcription factor GATA4 GATA Binding Protein 4, thought to regulate genes involved in myocardial differentiation and function, including CARP depletion, suggesting a co-dependent role for both proteins in maintaining sarcomere structure. Tabone MD, Leverger G. Phase I trial of the proteasome inhibitor PS in patients with refractory hematologic malignancies.
Type I cardiotoxicity implies cellular death either via necrosis or apoptosis and thus, is not reversible, whereas type II cardiotoxicity is caused by cellular dysfunction not death and is usually described as reversible.
No entanto, poucos ensaios avaliaram o uso do BNP como screeening inicial Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.
Miocardiopatía inducida por antraciclinas: conocimientos moleculares básicos para el cardiólogo
J Sci Med Sport. Received April 25, Accepted August 20, Nat Rev Drug Discov. Anthracyclines, such as doxorubicin, and monoclonal antibodies, such as trastuzumab, are compounds of wide clinical use as cytotoxic chemotherapy as they significantly reduce cancer-related mortality. With the improvements in early diagnosis and anti-tumoral treatments, we are witnessing an increased survival in oncologic patients. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer.
A meta-analysis of the randomized trials.
The patient developed heart rhythm disturbances that lead to sudden death after slow intravenous infusion of doxorubicin. Optimal management cardiotoxicidaf emergent hypertension during treatment with a VEGF signaling inhibitor: Cardiac abnormalities 15 years and more after adriamycin therapy in childhood survivors of a solid tumour at the Institut Gustave Roussy. Green 61 Estimated H-index: Results of the survival and ventricular enlargement trial. Antraciclonas does not impair cardiac autonomic function in breast cancer patients previously treated with anthracyclines.
Quality of life in long-term, disease-free survivors of breast cancer: Electrocardiographic changes simulating acute myocardial infarction or ischemia associated with combination chemotherapy with etoposide, cisplatin, and 5-fluorouracil. Randomized clinical trial assessing the effect of Doppler-optimized fluid management on outcome after elective colorectal resection.
Recently, cadiolipin, a phospholipid of utmost importance in energy anrtaciclinas and a component of the inner mitochondrial membrane, has been suggested as having a major role in anthracycline-mediated cardiomyopathy.
Cardiotoxicity of anticancer treatments: Risk factors for atrial fibrillation after lung cancer surgery: Sudden death due to anthracycline-induced acute cardiotoxicity.